PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q3–2026Q2) · Dividend yield is based on ₩0 per share · Prices as of the 2026-10-02 close
Amicogen's revenue shrank sharply on a narrower consolidation scope, but recent quarters show a revenue recovery and narrowing operating losses, even as two rounds of capital raises are reshaping the company's largest-shareholder structure.
2025 revenue fell sharply to KRW 41.98 billion from KRW 173.60 billion in 2024, mainly reflecting a narrower consolidation scope after divesting non-core subsidiaries.
Over the last five quarters (2025Q2-2026Q2), revenue rose from KRW 10.1bn to KRW 13.4bn while operating losses narrowed from about KRW -4.2bn to KRW -1.3bn.
A general public offering followed by a third-party share allocation in H1 2026 is set to make new investor YK Bionova Holdings the largest shareholder.
Media unit BeyondCell and resin unit Purigen anchor the company's bio-material localization strategy, though revenue contribution from these units remains at an early stage.
Repeated convertible bond issuance and early-redemption demands have kept liquidity pressure a recurring theme.
Amicogen grew out of a specialty pharmaceutical enzyme business (CX and DX enzymes, among others) built on gene-evolution technology.
The company runs a proprietary gene-evolution-based specialty enzyme business alongside healthcare materials, bio-pharmaceutical materials, and a finished health-supplement business under its own K-NUTRA brand.
In healthcare materials, it produces and sells functional ingredients such as PI/DCI, NAG, collagen peptide/tripeptide, and chitosan oligosaccharide (COS).
PI/DCI materials have reportedly been strengthening their position globally as an ingredient for PCOS (polycystic ovary syndrome), with new customers and sales volumes increasing in Southeast Asia and the United States.
Full-scale production at its Vietnam joint venture Aminavico is said to be reinforcing cost competitiveness and supply-chain stability, contributing to improving sales.
In bio-pharmaceutical materials, the company is pursuing localization of previously import-dependent bio-materials through its cell-culture media subsidiary BeyondCell and its antibody-purification resin subsidiary Purigen.
Its Chinese subsidiary, Amicogen (China) Biopharma, manufactures and sells immobilized carriers for specialty enzyme production, active pharmaceutical ingredients (APIs), finished drugs, and purification resins locally, and has also pursued cephalosporin and penicillin-class API businesses.
Competitively, the scarcity of domestic players with a proven commercialization track record in bio-materials such as media and resin represents both an entry barrier and a commercialization risk for the company.
| Quarter | Revenue | Operating profit | Op. margin |
|---|---|---|---|
| 2025Q2 | ₩10.1B | -₩4.2B | −41.8% |
| 2025Q3 | ₩10.1B | -₩4.7B | −46.1% |
| 2025Q4 | ₩10.9B | -₩3.9B | −35.8% |
| 2026Q1 | ₩12.3B | -₩3.2B | −25.8% |
| 2026Q2 | ₩13.4B | -₩1.3B | −9.7% |
| Year | Revenue | Operating profit | Net income (parent) | Op. margin | ROE | Debt-to-equity |
|---|---|---|---|---|---|---|
| 2022 | ₩144.3B | -₩4.9B | -₩47.2B | −3.4% | −35.8% | 153.1% |
| 2023 | ₩159.9B | ₩2.1B | -₩23.3B | 1.3% | −13.2% | 113.3% |
| 2024 | ₩173.6B | -₩7.1B | -₩52.8B | −4.1% | −43.1% | 139.0% |
| 2025 | ₩42B | -₩17.1B | -₩30B | −40.8% | −31.7% | 141.9% |
Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-08-23
Annual results show revenue of KRW 144.3bn (operating loss of KRW -4.90bn) in 2022, followed by a temporary swing to an operating profit of KRW 2.06bn (operating margin +1.3%) on revenue of KRW 159.9bn in 2023. In 2024, revenue grew to KRW 173.6bn but the company posted an operating loss of KRW -7.05bn again.
In 2025, revenue plunged to KRW 41.98bn and the operating loss widened to KRW -17.14bn (operating margin -40.8%), largely because divestitures and liquidations of subsidiaries narrowed the consolidation scope and reduced reported revenue.
Net income attributable to owners was negative for four straight years: KRW -47.22bn (2022), KRW -23.29bn (2023), KRW -52.79bn (2024) and KRW -29.96bn (2025).
On a quarterly basis, revenue rose steadily from KRW 10.15bn in 2025Q2 to KRW 10.14bn in 2025Q3, KRW 10.87bn in 2025Q4, KRW 12.28bn in 2026Q1 and KRW 13.39bn in 2026Q2, while the operating loss narrowed from about KRW -4.24bn to KRW -1.30bn over the same span.
Net income, however, diverged sharply from the operating trend: owners' net income swung to a large gain of KRW +19.70bn in 2026Q1 before reversing into a large loss of KRW -20.75bn in 2026Q2.
This wide swing in net income alongside a persistent operating loss suggests non-operating items (potentially related to fair-value changes on financial liabilities) played a significant role, and the underlying driver warrants confirmation from future disclosures.
On cash flow, operating cash flow deteriorated to KRW -24.42bn in 2025 from KRW -13.34bn in 2024, while 2023 stood out as the only year with positive operating cash flow at KRW +8.64bn.
Cell-culture media and antibody-purification resin—materials essential to biopharmaceutical manufacturing—have historically been largely import-dependent in Korea, prompting a government-led localization initiative under the Ministry of Trade, Industry and Energy.
The global chromatography resin market has reportedly continued growing on rising demand for therapeutic antibodies and increased R&D activity among biopharmaceutical companies.
The global cell-culture media market is also widely described as an area of steady annual growth, with domestic demand expanding alongside Korea's growing biopharmaceutical industry.
Amicogen is counted among the few domestic players attempting commercialization in this field, and its media-localization project was reportedly selected as an outstanding project in a government R&D evaluation. That said, commercial-scale sales performance remains at an early stage, which is cited as a key hurdle.
Competitively, large global material suppliers dominate most of the market, meaning that for a domestic latecomer, securing customer qualification (quality and GMP certification) and long-term contracts is the critical determinant of whether sales can meaningfully scale.
In H1 2026, Amicogen pursued two capital raises aimed at simultaneously improving its financial structure and reshaping its ownership base. The company said it plans to use part of the proceeds from these offerings to repay convertible bonds, with the remainder allocated to operating funds.
In June 2026, a disclosure confirmed a roughly KRW 10 billion third-party share allocation that would make YK Bionova Holdings the new largest shareholder, with an issue price of KRW 1,169 per share and 8,554,319 new shares allotted to the investor.
Whether the new largest shareholder brings governance stability or a strategic business partnership remains to be seen, depending on factors such as board representation and whether the existing management team stays in place.
Operationally, raising utilization at the media and resin plants, securing new customers, and expanding overseas sales channels for healthcare materials such as PI/DCI are cited as the key variables for a revenue recovery.
The company has previously outlined staged targets for scaling up resin sales, but given the 2025 full-year revenue level of KRW 41.98bn, progress against those targets warrants separate confirmation through future disclosures.
Recurring convertible-bond early-redemption issues appear to have eased somewhat, but call and put option schedules on remaining CBs continue, meaning liquidity management issues could persist for some time.
The current share price trades below the company's per-share net asset value, indicating the market is pricing the stock at a discount to book value. The company maintains a no-dividend policy, placing its dividend yield below the sector average.
With net losses persisting for several consecutive years, conventional earnings-multiple comparisons are difficult, and the recent narrowing of operating losses in quarterly results is a factor that could influence how the market assesses the path to earnings recovery going forward.
A number of outstanding convertible bonds carry conversion prices well above the current share price, so a wide gap between the two warrants attention as a potential trigger for early-redemption claims or further capital-raising needs.
The ongoing reshaping of the shareholder base through a capital raise tied to a change in largest shareholder is another factor worth weighing alongside valuation.
PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-08-23
Over the last five quarters (2025Q2-2026Q2), revenue climbed from KRW 10.1bn to KRW 13.4bn while the operating loss narrowed noticeably from about KRW -4.2bn to KRW -1.3bn. This suggests the business is stabilizing following the sharp revenue contraction seen in 2025 tied to a narrower consolidation scope.
If the narrowing-loss trend continues, market attention toward the possibility of approaching breakeven could increase.
Media subsidiary BeyondCell and resin subsidiary Purigen are positioned within a government-backed localization initiative for previously import-dependent bio-materials, with a related project reportedly selected as an outstanding project.
Given how few domestic players attempt commercialization in this field, the business is viewed as having growth potential if utilization rises and customer qualification is achieved. Depending on whether the new largest shareholder brings strategic investment, funding support for these businesses could also expand.
PI/DCI materials have reportedly been strengthening their global position as a PCOS-related ingredient, with new customers and sales volumes increasing in Southeast Asia and the United States.
Full-scale production at Vietnam joint venture Aminavico is reinforcing cost competitiveness and stabilizing the raw-material supply chain. This suggests the specialty enzyme and healthcare materials segment can act as a buffer for overall company performance.
Amicogen currently has a dispersed ownership structure without any single dominant shareholder, and its largest shareholder has changed multiple times within a short span—from the founder, to Maga Partners Investment Association, and now to YK Bionova Holdings.
Whether the new largest shareholder is a purely financial investor or a strategic partner remains unclear, and variables such as board representation plans and whether the existing management team stays in place remain to be determined. This governance uncertainty could weigh on execution capability and the pace of market-confidence recovery.
2025 revenue fell sharply to KRW 41.98bn from KRW 173.60bn in 2024, largely because subsidiary divestitures and liquidations aimed at securing liquidity narrowed the consolidation scope itself. While the divestitures raised some liquidity, they simultaneously shrank the revenue base.
Whether the remaining core businesses—media, resin, enzymes, and healthcare materials—can restore revenue to prior scale has yet to be proven.
Owners' net income posted losses for four consecutive years from 2022 to 2025, and the 2025 debt-to-equity ratio remained elevated at 141.9%. Frequent convertible bond issuance, responses to early-redemption claims, and repeated capital raises have been a constant burden on liquidity management.
The sharp swing between 2026Q1 and 2026Q2 net income also shows that earnings volatility driven by non-operating factors remains substantial.
A number of convertible bonds carry conversion prices well above the current share price, so if put options are exercised again, cash-repayment pressure could increase. The company had previously stated it would avoid dilutive capital raises, yet it carried out two share offerings in H1 2026. Should further funding be required, additional dilution cannot be ruled out.
The largest shareholder has changed multiple times in a short period, and the new largest shareholder, YK Bionova Holdings, is an entity that changed its business purpose to biotechnology only about a year after incorporation before deciding on this large investment; its specific strategic direction has not yet been fully disclosed to the market. If the largest shareholder's stake remains at a low level, concerns about management stability could resurface.
Utilization at the media and resin plants is reportedly rising more slowly than previously targeted, and the pace at which government-backed project achievements translate into actual commercial sales is a key variable.
Securing new customers and passing GMP quality verification can take time, raising the possibility that reaching the targeted revenue scale could be delayed.
The 2026 Q3 report should be checked to see whether the trend of rising revenue and narrowing operating losses continues, and whether media/resin revenue contribution becomes more concrete.
Watch whether new largest shareholder YK Bionova Holdings' board representation and the direction of any business cooperation (i.e., whether it acts as a strategic investor) become clearer.
As the 6th-issue convertible bond's call-option exercise window runs from August 2026 to February 2028 (seven occasions), related disclosures on redemption or cancellation should be monitored.
As Bifido's put-option window on the 6th-issue CB opens, the repayment method and funding plan should be confirmed.
Any disclosures or IR materials on new media/resin customer contracts and plant utilization can serve as evidence for gauging the pace of commercialization.
Amicogen's revenue scale shrank considerably in 2025 due to a narrower consolidation scope, but the last five quarters show a gradual revenue increase and a clear narrowing of operating losses.
That said, the sharp divergence between 2026Q1 and 2026Q2 net income illustrates that earnings volatility driven by non-operating factors remains substantial.
Two rounds of capital raises in H1 2026 are reshaping the ownership structure, and the role of new largest shareholder YK Bionova Holdings has emerged as a key variable for gauging future management direction.
The media and resin localization businesses have qualitative achievements such as selection for a government project, but their contribution to commercial revenue remains at an early stage, while frequent convertible bond issuance and responses to early-redemption demands have kept liquidity management under continuous pressure.
Expansion of overseas channels for healthcare materials and full-scale production at the Vietnam joint venture stand out as relatively stable buffering factors.
Investors should track whether the narrowing operating-loss trend continues in upcoming quarters, the strategic direction of the new largest shareholder, and the schedule of remaining convertible bond events.
Report written 2026-09-05 · Data as of 2026-09-04
This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.